A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2014
At a glance
- Drugs Trabectedin (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 01 May 2012 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2010 Actual end date (December 2009) added as reported by ClinicalTrials.gov.